According to a story from Healio, a recent phase 2 clinical trial found that treatment with vinorelbine plus active supportive care offered greater progression-free survival than active supportive care on…
According to a recent article from OncologyLive, investigators are looking at durvalumab to aid in the treatment of adults with malignant pleural mesothelioma in the Phase 3 DREAM3R Trial. Malignant…
A Phase 2 study examining the efficacy of patezolizumab and bevacizumab combined for malignant peritoneal mesothelioma (MPM) patients has just been published in the journal Cancer Discovery. The results demonstrated that…
According to a story from Pharma Times, a combination treatment consisting of nivolumab (marketed as Opdivo) plus ipilimumab (marketed as Yervoy) will now be available to UK patients living with…
Based on new data, the European Medicines Agency’s Committee for Medicinal Products for Human Use has designated nivolumab and ipilimumab as the frontline treatment for malignant pleural mesothelioma (MPM) in…
The FDA has just approved the very first therapy for malignant pleural mesothelioma (MPM) in more than 15 years. It is the NovoTTF-100L System, developed by Novocure. Not only is…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
